Radiation shielding structures comprising bulk-solidifying amorphous alloys and methods of making radiation shielding structures and components in near-to-net shaped forms are provided.

This invention relates to a tagged excavation element, and more particularly but not exclusively, to a tagged shroud or tooth of an excavation bucket. The invention also relates to a method of manufacturing a tagged excavation element, and to a method of detecting a tagged excavation element. The tagged excavation element includes an excavation element body and a tagging device securable to the excavation element body. The tagged excavation element is characterized in that the tagging device includes a radioactive source.

This invention relates to a tagged excavation element, and more particularly but not exclusively, to a tagged shroud or tooth of an excavation bucket. The invention also relates to a method of manufacturing a tagged excavation element, and to a method of detecting a tagged excavation element. The tagged excavation element includes an excavation element body and a tagging device securable to the excavation element body. The tagged excavation element is characterized in that the tagging device includes a radioactive source.

Systems and methods for determining an attenuation sinogram for a time-of-flight (TOF) positron emission tomography (PET) scan using only TOF PET data, and including use of the total amount of tracer provided to the subject of the TOF PET scan, are provided. The total amount of injected tracer can be used to determine the otherwise unknown constant shift present when an attenuation sinogram is estimated using the gradient of the attenuation sinogram. The attenuation sinogram can therefore be accurately and stably determined without any additional knowledge on the attenuation sinogram or map.

Systems and methods for determining an attenuation sinogram for a time-of-flight (TOF) positron emission tomography (PET) scan using only TOF PET data, and including use of the total amount of tracer provided to the subject of the TOF PET scan, are provided. The total amount of injected tracer can be used to determine the otherwise unknown constant shift present when an attenuation sinogram is estimated using the gradient of the attenuation sinogram. The attenuation sinogram can therefore be accurately and stably determined without any additional knowledge on the attenuation sinogram or map.

A method of preparing magnetite particles may include providing a first solution of substantially ferrous sulphate. The first solution may be converted by replacing sulphate ions with chloride ions to produce a second solution of substantially ferrous chloride. The second solution may be oxidized to produce a third solution of substantially iron oxide. A system for purifying a solution of substantially iron oxide may include a solution reservoir, at least one membrane unit, and at least one pump for circulating the solution between the solution reservoir and the membrane unit. The solution may be delivered from the solution reservoir to an inlet of the membrane unit, and/or the solution may be returned from an outlet of the membrane unit to the solution reservoir.

Embodiments of the disclosure include methods and compositions for treatment of prostate cancer, including metastatic prostate cancer or prostate cancer at risk for developing into metastatic prostate cancer, by providing an effective therapy to an individual that has been determined to have elevated levels of SRC-2 (also known as NCOA2, GRIP1 TIF2). In particular cases, sample from an individual known to have prostate cancer is assayed for the risk for developing metastatic prostate cancer and the individual is provided an effective therapy upon determination of elevated levels of SRC-2.

Embodiments of the disclosure include methods and compositions for treatment of prostate cancer, including metastatic prostate cancer or prostate cancer at risk for developing into metastatic prostate cancer, by providing an effective therapy to an individual that has been determined to have elevated levels of SRC-2 (also known as NCOA2, GRIP1 TIF2). In particular cases, sample from an individual known to have prostate cancer is assayed for the risk for developing metastatic prostate cancer and the individual is provided an effective therapy upon determination of elevated levels of SRC-2.

The present invention is directed to methods of determining the presence or absence of a bacterial infection in a patient using isotopically-labeled tyrosine and/or isotopically-labeled p-hydroxyphenylacetic acid.

Described herein is an alpha-emitting radionuclide, .sup.211At, which has been incorporated into a selective sigma-2 ligand moiety to provide cytotoxic capabilities to a chemical compound. As described herein, a compound of formula (I), wherein R.sup.1-R.sup.4, m, and n are defined herein, was prepared and utilized in in vitro and in vivo tumor targeting of alpha-emitting sigma-2 ligand in a breast cancer model. In one embodiment, the compound is 5-(.sup.211At)N-(4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-2,3-dimethoxybenzamide.

##STR00001##